This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713618290

Synthesis of Some New Pyrazolo[3,4-d]pyrimidines and Thiazolo [4,5-d]pyrimidines and Evaluation of Their Antimicrobial Activities

J. D. Akbari^a; S. D. Tala^a; M. F. Dhaduk^a; H. S. Joshi^a; K. B. Mehta^b; S. J. Pathak^b

^a Department of Chemistry, Saurashtra University, Rajkot, India ^b Department of Bio-Science, Saurashtra University, Rajkot, India

To cite this Article Akbari, J. D. , Tala, S. D. , Dhaduk, M. F. , Joshi, H. S. , Mehta, K. B. and Pathak, S. J. (2008) 'Synthesis of Some New Pyrazolo [3,4-d] pyrimidines and Thiazolo [4,5-d] pyrimidines and Evaluation of Their Antimicrobial Activities', Phosphorus, Sulfur, and Silicon and the Related Elements, 183: 6, 1471 - 1477

To link to this Article: DOI: 10.1080/10426500701681581 URL: http://dx.doi.org/10.1080/10426500701681581

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Phosphorus, Sulfur, and Silicon, 183:1471-1477, 2008

Copyright © Taylor & Francis Group, LLC ISSN: 1042-6507 print / 1563-5325 online

DOI: 10.1080/10426500701681581



Synthesis of Some New Pyrazolo[3,4-d]pyrimidines and Thiazolo [4,5-d]pyrimidines and Evaluation of Their Antimicrobial Activities

J. D. Akbari, S. D. Tala, M. F. Dhaduk, H. S. Joshi, K. B. Mehta, and S. J. Pathak

 $^1{\rm Department}$ of Chemistry, Saurashtra University, Rajkot, India $^2{\rm Department}$ of Bio-Science, Saurashtra University, Rajkot, India

The desired fused ring system 3-isopropyl-4-aryl-1,4,5,7-tetrahydro-pyrazolo[3,4-d]pyrimidine-6-thiones 4a-d were synthesized by the reaction of 5-isopropyl-2,4-dihydro-3-pyrazolone 1, thiourea and different aromatic aldehydes, while 7-aryl-5-thioxo-4,5,6,7-tetrahydro-3H-thiazolo[4,5-d]pyrimidin-2-ones 7a-d were synthesized by using 2,4-thiazolidine 5 instead of 5-isopropyl-2,4-dihydro-3-pyrazolone 1. The structure of the compounds was assigned on the basis of elemental analysis, IR, 1H-NMR, and mass spectroscopy. The antibacterial activity of the newly synthesized compounds were tested against Staphylococcus aureus ATCC 6538, Staphylococcus epidermidis ATCC 12228, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 1539, and their antifungal activity against Candida albicans ATCC 10231 were tested using the disk diffusion method. Compounds 4b, 4c, 4d, 7c and 7d were found to be active against S. aureus ATCC 6538 (MIC: 185; 78; 156; 78; and 102 µg/Ml, respectively) and compounds 4d and 7d against C. albicans ATCC 10231 (MIC: 312.5 µg/mL). The minimum inhibitory concentration of these compounds was determined using the micro dilution method.

Keywords Antimicrobial activities; pyrazolo[3,4-d]pyrimidines; thiazolo[4,5-d]pyrimidines

INTRODUCTION

Pyrimidine and their derivatives are well known for their potential biological activity such as fungiside¹, algaecide,² and as antibiotic.³ Similarly thiazoles have shown wide range of applications,⁴ in drug

Received 10 July 2007; accepted 3 August 2007.

We thank to Department of Chemistry, Saurashtra University, Rajkot for providing facilities and Department of Bio-Sciences, for antimicrobial screening. We are also thankful to CIL, RSIC, Chandigarh for providing spectral analysis of compounds.

Address correspondence to H. S. Joshi, Department of Chemistry, Saurashtra University, Rajkot 360005, India. E-mail: drhsjoshi49@gmail.com

development,⁵ against inflammation,⁶ bacterial,⁷ and HIV infection,⁸ and pyrazolones are also used as starting materials for the synthesis of biologically active compounds, 9 as well as for the construction of condensed heterocyclic systems. 10,11 This inspired us to synthesize 3-isopropyl-4-aryl-1,4,5,7-tetrahydro-pyrazolo[3,4-d]pyrimidine-6thiones **4a-d** and 7-aryl-5-thioxo-4.5.6.7-tetrahydro-3*H*-thiazolo [4.5dlpyrimidin-2-ones 7a-d. In the literature it was shown that when pyrazolone or rhodanine react with different aromatic aldehydes and thiourea at reflux temperature, new derivatives are formed. 12,13 In this work, in line with literature findings, 5-isopropyl-2,4-dihydro-3pyrazolone^{14,15} or 2,4-thiazolidine¹⁶ when react with different aromatic aldehydes 2 and thiourea afforded desired product. The antibacterial activity of the new compounds against Staphylococcus aureus ATCC 6538, Staphylococcus epidermidis ATCC 12228, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 1539, and antifungal activity against Candida albicans ATCC 10231 were investigated.

RESULTS AND DISCUSSION

Condensation of 5-isopropyl-2,4-dihydro-3-pyrazolone **1** or 2,4-thiazolidine **5** with different aromatic aldehydes by Knoevenagel condensation in the presence of piperidine at reflux temperature to give 4-benzylidene-5-isopropyl-2,4-dihydro-3-pyrazolone **3a-d** or benzylidene-thiazolidine-2,4-dione **6a-d** respectively. Which were on reflux with thiourea in ethanolic HCl to yield 3-isopropyl-4-aryl-1,4,5,7-tetrahydro-pyrazolo[3,4-d]pyrimidine-6-thiones **4a-d** and 7-aryl-5-thioxo-4,5,6,7-tetrahydro-3*H*-thiazolo[4,5-*d*]pyrimidin-2-ones **7a-d** respectively (Schemes 1 and 2).

$$H_3C$$
 H_3C
 H_3C

SCHEME 1 Synthesis of substituted pyrazolo[3,4-d]pyrimidine.

The formulas of the compounds were confirmed by the elemental analysis and their structures were determined by IR, ¹H-NMR, and mass spectral data. The IR spectra of the compounds displayed the characteristic N-H stretching vibration at 3474–3448 cm⁻¹. The ¹H-NMR spectrums of selected compounds give its characterized peak in

Where $R = 4\text{-OCH}_3$, 2-OCH₃, and 3,4-(OCH₃)

SCHEME 2 Synthesis of substituted thiazolo[4,5-d]pyrimidine.

particular region. Mass of all compounds was taken, and it was shown molecular ion peak (M^+) with low intensity.

Experiment were performed to evaluate the antibacterial activity against Staphylococcus aureus ATCC 6538, Staphylococcus epidermidis ATCC 12228, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 1539, antifungal activity against Candida albicans ATCC 10231 were tested using the disk diffusion method. Compounds 4b, 4c, 4d, 7c and 7d were found to be active against S. aureus ATCC 6538 and compounds 4d and 7d against C. Albicans ATCC 10231. The minimum inhibitory concentration of these compounds was determined using the micro dilution method. As a result, four compounds were found to be active. The most active compound was compound 4c, which had a methoxy group on 2nd position of the phenyl ring, while the least active one, 4b. The compounds 4a, 7a, and 7b did not show any activity. The MIC values of the compounds 4b, 4c, 4d, 7c, and 7d against S. aureus ATCC 6538 were 185; 78; 156; 78; and 102 μ g/mL, respectively, and the compounds 4d and 7p against C. albicans ATCC 10231 were both 312.5 μ g/mL (Table I).

TABLE I MIC Values (μ g/mL) of Compounds 4b, 4c, 4d, 7c, and 7d

Compound	S. aureus ATTC 6535	C. albicans ATCC 10231
4b	185	_
4c	78	_
4d	156	312.5
7c	78	_
7d	102	312.5
Cefuroxim Na	1.2	2.4

EXPERIMENTAL SECTION

General Procedures

Melting points were estimated in open capillaries and are uncorrected. Elemental analyses were performed on a Carlo Erba EA 1108 elemental analyzer. IR spectra were recorded on KBr discs, using FTIR-8400 spectrophotometer. $^1\mathrm{H}\text{-}\mathrm{NMR}$ spectra were taken on a Bruker AVANCE II 400 ($^1\mathrm{H}$: 400 Mz, [d₆] DMSO) spectrometer. Mass spectra were determined on a GCMS-QP2010 mass spectrometer.

General Procedure for the Preparation of 3-Isopropyl-4-aryl-1,4,5,7-tetrahydro-pyrazolo[3,4-d]pyrimidine-6-thiones (4a–d)

A mixture of 5-isopropyl-2,4-dihydro-3-pyrazolone (0.01 mol) 1 and aromatic aldehyde 2 (0.01 mol) was taken in round bottom flask (100 mL) containing 10 mL of ethanol, heated under reflux for 30 min and add pyridine (1 mL) in reaction mixture. Further refluxed it for 5 h; thus, the solid product was separated, filtered off and washed with cold mixture of ethanol:water (1:1) to give product 3a–d. The crude products were purified by crystallization from 95% ethanol to afford pure product.

Product **3a–d** (0.01 mol), thiourea (0.011 mol) and ethanolic HCl 10 mL (0.01N) was reflux for 5–6 h and separated solid was isolate from RBF, washed with ethanol (5mL) and crystallized from ethanol to get **4a–d.**

3-lsopropyl-4-phenyl-1,4,5,7-tetrahydro-pyrazolo[3,4-d]pyrimidine-6-thione (4a)

Yellow crystals (1.03 g, 38%); m.p. 245=248°C. IR (KBr): v 3447 (—NH), 3232 (ArH), 2925 (C—H str.), 1439 (C—H i.p.def.) cm⁻¹. ¹H NMR (400 MHz, DMSO- d_6): δ 1.12 (3H, d, J = 6.92 Hz, CH₃), 1.19 (3H, d, J = 6.8 Hz, CH₃), 2.95 (1H, m, —CH), 6.50—7.42 (6H, m, ArH), 7.84 (1H, s, NH-pyrazole), 8.58 (1H, s, NH pyrimidine), 8.84 (1H, s, NH pyrimidine). Mass M⁺¹273. Anal. calcd. for C₁₄H₁₆N₄S: C, 61.74; H, 5.92, N, 20.57. Found: C, 61.22; H, 5.56, N, 20.74.

3-lsopropyl-4-(4-methoxyphenyl)-1,4,5,7-tetrahydro-pyrazolo [3,4-d]pyrimidine-6-thione (4b)

Yellow powder (1.26 g, 42%); m.p. 221=222°C. IR (KBr): v 3447 (-NH), 3243 (ArH), 2934 (C—H str.), 1436 (C—H i.p.def.) cm $^{-1}$. $^1{\rm H}$ NMR (400 MHz, DMSO- d_6): δ 1.14 (3H, d, J=7 Hz, CH₃), 1.23 (3H, d, J=6.88 Hz, CH₃), 2.99 (1H, m, —CH), 3.83 (3H, s, OCH₃), 6.57=7.35 (5H, m, ArH), 7.03 (1H, s, NH-pyrazole), 8.55 (1H, s, NH pyrimidine), 8.82

(1H, s, NH pyrimidine). Mass M^+303 . Anal. calcd. for $C_{15}H_{18}N_4OS$: C, 59.58; H, 6.00, N, 18.25. Found: C, 60.89; H, 5.83, N, 18.77.

3-lsopropyl-4-(2-methoxyphenyl)-1,4,5,7-tetrahydro-pyrazolo[3,4-d]pyrimidine-6-thione (4c)

Light yellow powder (0.96 g, 32%); m.p. 233=235°C. IR (KBr): v 3420 (-NH), 3309 (ArH), 2925 (C—H str.), 1461 (C—H i.p.def.) cm $^{-1}$. 1 H NMR (400 MHz, DMSO- d_6): δ 1.12 (3H, d, J = 6.96 Hz, CH $_3$), 1.21 (3H, d, J = 6.88 Hz, CH $_3$), 2.97 (1H, m, —CH), 3.82 (3H, s, OCH $_3$), 6.52-7.30 (5H, m, ArH), 7.44 (1H, s, NH-pyrazole), 8.79 (1H, s, NH pyrimidine), 9.01 (1H, s, NH pyrimidine). Mass M $^+$ 303. Anal. calcd. for C $_{15}$ H $_{18}$ N $_{4}$ OS: C, 59.58; H, 6.00, N, 18.25. Found: C, 59.31; H, 5.82, N, 18.32.

3-lsopropyl-4-(3,4-dimethoxyphenyl)-1,4,5,7-tetrahydropyrazolo[3,4-d]pyrimidine-6-thione (4d)

Orange crystals (1.56 g, 47%); m.p. 241=242°C. IR (KBr): v 3421 (-NH), 3276 (ArH), 2932 (C–H str.), 1433 (C–H i.p.def.) cm⁻¹. ¹H NMR (400 MHz, DMSO- d_6): δ 1.15 (3H, d, J = 6.96 Hz, CH₃), 1.23 (3H, d, J = 6.88 Hz, CH₃), 3.00 (1H, m, -CH), 3.83 (3H, s, OCH₃), 3.88 (3H, s, OCH₃), 6.53-6.92 (4H, m, ArH), 7.47 (1H, s, NH-pyrazole), 7.82 (1H, s, NH pyrimidine), 8.01 (1H, s, NH pyrimidine). Mass M+316. Anal. calcd. for C₁₆H₂₀N₄O₂S: C, 57.18; H, 6.06, N, 16.85. Found: C, 57.34; H, 5.97, N, 16.77.

General Procedure for the Preparation of 7-Aryl-5-thioxo-4,5,6,7-tetrahydro-3H-thiazolo[4,5-d]pyrimidin-2-ones (7a-d)

A mixture of 2,4-thiazolidinone (0.01 mol) **5** and aromatic aldehyde **2** (0.01 mol) was taken in round bottom flask (100 mL) containing 10 mL of ethanol, heated under reflux for 30 min and add pyridine (1 mL) in reaction mixture. Further refluxed it for 5 h, thus the solid product was separated, filtered off and washed with cold mixture of ethanol:water (1:1) to give product **6a–d**. The crude products were purified by crystallization from 95% ethanol to afford pure product.

Product **6a-d** (0.01 mol), thiourea (0.011 mol) and ethanolic HCl 10 mL (0.01N) was reflux for 5–6 h and separated solid isolate from RBF, washed with ethanol (5mL) and crystallized from ethanol to get **7a-d.**

7-Phenyl-5-thioxo-4,5,6,7-tetrahydro-3H-thiazolo[4,5-d]pyrimidin-2-one (7a)

Light yellow crystals (1.08 g, 41%); m.p. 219–220°C. IR (KBr): v 3474 (-NH), 3232 (ArH), 1733 (C=O) cm⁻¹. ¹H NMR (400 MHz, DMSO- d_6): 6.50–7.90 (6H, m, ArH), 10.03 (1H, s, NH-thiazole), 10.84 (1H, s, NH

pyrimidine), 11.15 (1H, s, NH pyrimidine). Mass M^+264 . Anal. calcd. for $C_{11}H_9N_4OS_2$: C, 50.17; H, 3.44, N, 15.96. Found: C, 49.88; H, 3.32, N, 15.85.

7-(4-Methoxyphenyl)-5-thioxo-4,5,6,7-tetrahydro-3H-thiazolo [4,5-d]pyrimidin-2-one (7b)

Orange crystals (1.46 g, 50%); m.p. 215–216°C. IR (KBr): v 3448 (-NH), 3232 (ArH), 1742 (C=O) cm $^{-1}$. 1 H NMR (400 MHz, DMSO- d_6): 3.86 (3H, s, CH₃), 698–7.72 (5H, m, ArH), 10.03 (1H, s, NH-thiazole), 11.04 (1H, s, NH pyrimidine), 11.15 (1H, s, NH pyrimidine). Mass M+294. Anal. calcd. for $C_{12}H_{11}N_3O_2S_2$: C, 49.13; H, 3.78, N, 14.32. Found: 49.32; H, 3.88, N, 14.21.

7-(2-Methoxyphenyl)-5-thioxo-4,5,6,7-tetrahydro-3H-thiazolo [4,5-d]pyrimidin-2-one (7c)

Orange crystals (0.82 g, 28%); m.p. 196–197°C. IR (KBr): v 3416 (-NH), 3232 (ArH), 1734 (C=O) cm⁻¹. ¹H NMR (400 MHz, DMSO- d_6): 3.82 (3H, s, CH₃), 6.52–7.30 (5H, m, ArH), 10.03 (1H, s, NH-thiazole), 11.22, s, NH pyrimidine), 11.32 (1H, s, NH pyrimidine). Mass M⁺294. Anal. calcd. for C₁₂H₁₁N₃O₂S₂: C, 49.13; H, 3.78, N, 14.32. Found: C, 49.21; H, 3.75, N, 14.45.

7-(3,4-Dimethoxyphenyl)-5-thioxo-4,5,6,7-tetrahydro-3H-thiazolo[4,5-d]pyrimidin-2-one (7d)

Yellow crystals (1.29 g, 40%); m.p. 214–215°C. IR (KBr): v 3448 (-NH), 3232 (ArH), 1727 (C=O) cm⁻¹. Mass M⁺324. Anal. calcd. for $C_{13}H_{13}N_3O_3S_2$: C, 48.28; H, 4.05, N, 12.99. Found: C, 48.41; H, 4.22, N, 12.76.

Microbiology

Derivatives **4a–d** and **7a–d** were tested in vitro for antimicrobial activity *S. aureus* ATCC 6538, *S. epidermidis* ATCC 12228, *E. coli* ATCC 8739, *P. aeruginosa* ATCC 1539, and antifungal activity against *C. albicans* ATCC 10231 using the disk diffusion method where each disc contained 200 μ g of the tested compound. For this method, Mueller-Hinto agar (Difco) was melted at 100° C and after cooing to 56° C, was poured into Petri plates of 9 cm diameter in quantities of 20 mL, and left on a flat surface to solidify and the surface of the medium was dried at 37° C. Then, the cultures of each bacteria and yeast strain, after being kept in Mueller-Hinton broth (Difco) at 37° C for 18-24 h and diluted with Mueller-Hinton broth to 10^{5} cfu/mL, were pipetted into the Mueller-Hinton agar plate prepared as described above. The surface of the medium was allowed to dry. The $10,000 \, \mu$ g/mL (in DMSO) compound

impregnated discs were applied to the surface of inoculated plates. The Petri plates were placed in an incubator at 37°C. After 10–24 h of incubation, the Petri plates were examined and it was found that compounds **4b**, **4c**, **4d**, **7c**, and **7d** were active against S. aureus ATCC 6539 and compounds **4d** and **7d** against *C. albicans* ATCC 10231.

The minimum inhibitory concentrations (MIC) of these compounds were determined by the microbroth dilution technique using Mueller-Hinton broth. Serial two-fold dilution ranged from 2500 to 2.4 mg/L for compounds.

The inoculum was prepared in broth, which had been diluted with Mueller-Hinton broth to give a final concentration of 10^5 cfu/mL in the test tray. The trays were covered and placed in plastic bags to prevent drying. After incubation at 37° C for 18-24 h, the MIC was defi3ed as the lowest concentration of compound giving complete inhibition of visible growth. MIC values of the compounds are given in Table I.

REFERENCES

- F. Russo, M. Santagati, A. Santagoti, and G. Blandino, Farmaco Ed. Sci., 36, 983 (1981); Chem. Abstr., 97, 6226c (1982).
- [2] C. R. Kramer, D. Heydenhass, G. Jaenicke, and M. Henez, Ger. DD., 22, 6757 (1985); Chem. Abstr., 104, 64211t (1986).
- [3] Haruoo, H. Kosuzume, M. Mizota, Y. Suzuki, and E. Mochida, Eur. Pat. Appl., EP., 150507 (1985); Chem. Abstr., 104, 68678 (1986).
- [4] M. P. Mohinder and D. Dey Paramita, *Indian J. Chem.*, **41B**, 1286 (2002).
- [5] W. C. Patt, H. W. Hamilton, and M. D. Taylor, J. Med. Chem., 35, 2562 (1992).
- [6] F. Haviv, R. W. DeNet, and G. W. Carter, J. Med. Chem., 31, 1719 (1988).
- [7] K. Tsuji and H. Ishikawa, Med. Chem. Lett., 4, 1601 (1994).
- [8] F. W. Bell, M. Hoberg, and X-X. Zhou, J. Med. Chem., 38, 4959 (1995).
- [9] P. Chiba, W. Holzer, M. Landau, G. Bechmann, K. Lorenz, B. Plagens, M. Hitzler, E. Richter, and G. Ecker, J. Med. Chem., 41, 4001 (1998).
- [10] (a) K. Kirschke, 1H-Pyrazole.In Houben-Weyl: Methoden der Organischen Chemie; (Thieme: Stuttgart, New York, 1994) Vol. E8b, pp. 399–763; (b) B. Stanovnik and J. Svete, Pyrazoles, In Science of Synthesis: Houben-Weyl Methods of Molecular Transformations (Thieme: Stuttgart-New York, 2002) Vol. 12, pp 15–225.
- [11] (a) S. Gelin, B. Chantegrel, and A. I. Nadi, J. Org. Chem., 48, 4078 (1983); (b) B. Chantegrel, A. I. Nadi, and S. Gelin, Synthesis, 844 (1983).
- [12] S. Vineeta, K. Vineeta, C. Sanjana, and G. Urmila, *Indian J. Het. Chem.*, 15, 305 (2006).
- [13] A. S. Sagir and V. V. Dabholkar, *Indian J. Chem.*, **43B**, 2646 (2004).
- [14] J. Funaki, K. Imai, K. Araki, A. Danel, and P. Tomasik, Polish J. Chem., 78, 843 (2004).
- [15] (a) A. I. Vogel, Vogels Textbook of Practical Organic Chemistry (ELBS, Longman Singapore Publisher Pvt. Ltd., Singapore, 1994), 5th ed., pp 807; (b) V. K. Ahluwalia, Intermediates for Organic Synthesis (I. K. International Pvt. Ltd., New Delhi, 2005), pp. 269.
- [16] I. Sawhney and J. R. H. Wilson, J. Chem. Soc., Perkin Trans. 1, 972 (1992).